Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges

Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges

Editor(s): Stefan R. Schmidt

Published Online: 12 FEB 2013 10:40AM EST

Print ISBN: 9780470646274

Online ISBN: 9781118354599

DOI: 10.1002/9781118354599

About this Book

The state of the art in biopharmaceutical FUSION PROTEIN DESIGN

Fusion proteins belong to the most lucrative biotech drugs—with Enbrel® being one of the best-selling biologics worldwide. Enbrel® represents a milestone of modern therapies just as Humulin®, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and Orthoclone® the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protein was launched.

Fusion Protein Technologies for Biopharmaceuticals examines the state of the art in developing fusion proteins for biopharmaceuticals, shedding light on the immense potential inherent in fusion protein design and functionality. A wide pantheon of international scientists and researchers deliver a comprehensive and complete overview of therapeutic fusion proteins, combining the success stories of marketed drugs with the dynamic preclinical and clinical research into novel drugs designed for as yet unmet medical needs.

The book covers the major types of fusion proteins—receptor-traps, immunotoxins, Fc-fusions and peptibodies—while also detailing the approaches for developing, delivering, and improving the stability of fusion proteins. The main body of the book contains three large sections that address issues key to this specialty: strategies for extending the plasma half life, the design of toxic proteins, and utilizing fusion proteins for ultra specific targeting. The book concludes with novel concepts in this field, including examples of highly relevant multifunctional antibodies.

Detailing the innovative science, commercial realities, and brilliant potential of fusion protein therapeutics, Fusion Protein Technologies for Biopharmaceuticals is a must for pharmaceutical scientists, biochemists, medicinal chemists, molecular biologists, pharmacologists, and genetic engineers interested in determining the shape of innovation in the world of biopharmaceuticals.

Table of contents

    1. You have free access to this content
  1. Part I: Introduction

  2. Part II: The Triple T Paradigm: Time, Toxin, Targeting - IIA: Time: Fusion Protein Strategies For Half-Life Extension

    1. Chapter 7

      Monomeric Fc-Fusion Proteins (pages 107–121)

      Baisong Mei, Susan C. Low, Snejana Krassova, Robert T. Peters, Glenn F. Pierce and Jennifer A. Dumont

    2. Chapter 14

      ELP-Fusion Technology for Biopharmaceuticals (pages 211–226)

      Doreen M. Floss, Udo Conrad, Stefan Rose-John and Jürgen Scheller

    3. Chapter 15

      Ligand-Receptor Fusion Dimers (pages 227–235)

      Sarbendra L. Pradhananga, Ian R. Wilkinson, Eric Ferrandis, Peter J. Artymiuk, Jon R. Sayers and Richard J. Ross

    4. Chapter 16

      Development of Latent Cytokine Fusion Proteins (pages 237–252)

      Lisa Mullen, Gill Adams, Rewas Fatah, David Gould, Anne Rigby, Michelle Sclanders, Apostolos Koutsokeras, Gayatri Mittal, Sandrine Vessillier and Yuti Chernajovsky

  3. Part II: The Triple T Paradigm: Time, Toxin, Targeting - IIB: Toxin: Cytotoxic Fusion Proteins

    1. Chapter 21

      Immunokinases (pages 329–336)

      Stefan Barth, Stefan Gattenlöhner and Mehmet Kemal Tur

    2. Chapter 24

      Tumor-Targeted Superantigens (pages 365–381)

      Gunnar Hedlund, Göran Forsberg, Thore Nederman, Anette Sundstedt, Leif Dahlberg, Mikael Tiensuu and Mats Nilsson

  4. Part II: The Triple T Paradigm: Time, Toxin, Targeting - IIC: Targeting: Fusion Proteins Addressing Specific Cells, Organs, and Tissues

    1. Chapter 26

      Cell-Penetrating Peptide Fusion Proteins (pages 397–411)

      Andrés Muñoz-Alarcón, Henrik Helmfors, Kristin Karlsson and Ülo Langel

  5. Part III: Beyond the Triple T-Paradigm - IIIA: Novel Concepts, Novel Scaffolds

    1. Chapter 33

      Amediplase (pages 507–518)

      Stefano Evangelista and Stefano Manzini

  6. Part III: Beyond the Triple T-Paradigm - IIIB: Multifunctional Antibodies

    1. Chapter 36

      Novel Applications of Bispecific DART® Proteins (pages 545–555)

      Syd Johnson, Bhaswati Barat, Hua W. Li, Ralph F. Alderson, Paul A. Moore and Ezio Bonvini

    2. Chapter 38

      CovX-Bodies (pages 571–582)

      Abhijit Bhat, Olivier Laurent and Rodney Lappe

    1. You have free access to this content